Latus Bio
3 known investors
Find your way into Latus Bio
Latus develops gene therapies based on novel AAV capsid variants matched to optimized routes of administration, aiming to target specific cell types and tissues to lower dose requirements, toxicity, and manufacturing costs. It focuses on treating monogenic diseases affecting the central nervous system and peripheral tissues using computational methods and unbiased capsid screening.
Investors · 3
Funding
SEC filings, press & company announcements$97M disclosed across 1 round · 2026
- $97MraisedMay 2026 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Latus Bio do?
- Latus develops gene therapies based on novel AAV capsid variants matched to optimized routes of administration, aiming to target specific cell types and tissues to lower dose requirements, toxicity, and manufacturing costs. It focuses on treating monogenic diseases affecting the central nervous system and peripheral tissues using computational methods and unbiased capsid screening.
- Who are Latus Bio's investors?
- Latus Bio's investors include 8VC, DCVC (Data Collective), Modi Ventures.
- How much funding has Latus Bio raised?
- Latus Bio has disclosed $97M raised across 1 round.